Supportato da studi clinici e ricerche condotte in modo indipendente

The parasympathetic nervous system is the body’s internal relaxation & rest mechanism. HRV is an indicator of Vagus Nerve activity. Improving these parameters of HRV indicates targeted stimulation of the vagus nerve and activation of specific self-repair mechanisms of body & mind. In a clinical trial, a one-hour session of Nurosym favourably altered all three parameters of Heart Rate Variability (HRV), when compared to a placebo. Figure (a) shows High Frequency HRV is significantly increased ('p=0.001). Figure (b) shows Low-Frequency HRV is significantly decreased ('P=0.001). Figure (c) shows the ratio of LF to HF is significantly decreased (*p=0.002).

Nurosym neuromodulation has demonstrated a beneficial effect on fatigue by modulating the autonomic nervous system, leading to enhanced energy levels and reduced sensations of exhaustion. In the study, patients reported sustained improvements even one week after discontinuing the therapy, indicating prolonged relief from fatigue-related symptoms.(Figure) Fatigue was assessed using the Pichot fatigue scale scores during therapy (D0: day 0, D5: day 5 and D10: day 10). The results revealed a substantial reduction in fatigue, registering approximately 48% improvement (D0 vs. D10, p < 0.0001) after Nurosym neuromodulation therapy.

A growing body of research suggests that vagus nerve regulation plays a crucial role in managing chronic inflammation. Nurosym, through the stimulation of afferent vagus nerve fibres, has been shown to influence higher brain structures. This modulation may help alleviate symptoms connected to Post-viral Fatigue Syndrome such as chronic fatigue, pain, and brain fog.(Figure ) A very significant improvement in Post-viral Fatigue symptoms was observed after 10 neuromodulation therapy sessions. (D0 vs. D10: p < 0.0001).

Individuals with attention deficits, including those diagnosed with ADHD, often exhibit low heart rate variability (HRV) measurements, indicating reduced vagus nerve activity and diminished parasympathetic tone. Nurosym neuromodulation counteracts the persistent sympathetic "fight-or-flight" overdrive, thereby enhancing cognitive function.(Figure) Changes in attention were assessed using the Flanker Inhibitory Control and Attention assay across three timepoints: pre-intervention, post-intervention, and 1-month follow-up. After Nurosym therapy, significant gains were detected from pre-intervention to post-intervention (p < 0.01) and from pre-intervention to follow-up (p < 0.001).

Biologically, the vagus nerve inhibits oxidative stress, inflammation and sympathetic activity (and associated hypoxia). Nurosym led to a significant decrease in reactive oxygen species (ROS) (p = 0.004), while placebo stimulation did not cause a significant change (p = 0.10).(Figure) Change in median DCF values from admission to discharge in the Nurosym group compared to the placebo group (p < 0.005).

Researchers have demonstrated a direct link between vagus nerve stimulation and the activation of learning centres in the brain. This discovery has led to the evaluation of Nurosym neuromodulation, which has been shown to enhance cognitive retention in both healthy individuals and those with injured nervous systems.(Figure) Nurosym neuromodulation paired with training significantly (*p < 0.05) improved speed performance on the Automaticity learning task compared to placebo controls. Nurosym neuromodulation also significantly (∗p < 0.05) improved percent correct on the Decoding learning task as compared to controls.

The vagus nerve modulates the inflammatory response, thereby reducing the systemic inflammatory burden that contributes to the progression of various diseases, including atrial fibrillation. Leveraging this mechanism, Nurosym neuromodulation offers a non-invasive modality for regulating cardiac rhythm, effectively suppressing atrial fibrillation.(Figure) Comparison of atrial fibrillation (AF) burden between the two groups (Nurosym neuromodulation vs Placebo stimulation) is presented using interquartile range values. The p-value reflects the comparison of median AF burden levels at the 6-month mark, adjusted for baseline measurements.

The purpose of the study was to determine the influence of vagal innervation control of the resting diameter of large blood vessels using Nurosym neuromodulation. Nurosym has demonstrated a significant ability to enhance blood circulation and macrovascular endothelial function compared to a placebo.(Figure) Percent change in flow-mediated vasodilation (FMD) with Nurosym. "Before" and "after" refer to the brachial artery (BA) diameter and FMD test conducted pre- and post-Nurosym neuromodulation. The y-axis shows the percent change in BA diameter. The box shows the 25th–75th percentile, the middle line is the median, the dot is the mean, and the bars indicate the maximum and minimum values.

The use of Nurosym may positively influence cardio-vagal baroreflex gain (BRS) in patients with chronic heart failure (CHF). BRS, a marker of autonomic function, is often impaired in CHF, contributing to poor outcomes. Enhancing BRS through Nurosym could improve parasympathetic tone, stabilise cardiovascular regulation, and potentially mitigate disease progression. (Figure) Acute AVNT significantly increased cardio-vagal baroreflex gain in the study population, demonstrating its potential to enhance autonomic cardiovascular regulation in patients with chronic heart failure.